Search filters

List of works by Ana Arance

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

scientific article

Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process

scientific article published on 01 February 2007

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

scientific article published on 10 September 2017

Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors

scientific article

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

scientific article published on 20 December 2018

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

scientific article published on 8 March 2017

CDC group IV c-2 infection in a stem cell transplant recipient

scientific article published on 01 December 1997

Clinical implications of the intrinsic molecular subtypes of breast cancer

scientific article

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

scientific article

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

scientific article published on 13 March 2018

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

scientific article

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

scientific article published in December 2017

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

scientific article published on 02 June 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

scientific article published on 5 May 2017

Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.

scientific article

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

scientific article

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

scientific article

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study

scientific article

Genomic analysis and clinical management of adolescent cutaneous melanoma

scientific article

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

scientific article published on 16 October 2013

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

scientific article published on 19 May 2017

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

scientific article published on 17 March 2015

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

scientific article published on 9 May 2017

Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment.

scientific article published in October 2017

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

scientific article published on 01 December 2021

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

scientific article published on 27 March 2017

Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.

scientific article published on September 2016

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

scientific article published on December 2014

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

scientific article published on 15 August 2014

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.

scientific article published on 8 February 2016

Nivolumab in previously untreated melanoma without BRAF mutation

scientific article (publication date: 22 January 2015)

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study

scientific article

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

scientific article

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 12 September 2018

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

scientific article published on 4 January 2017

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

scientific article

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

scientific article

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

scientific article published on 13 June 2017

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

scientific article published on 01 February 2000

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

scientific article published on July 2003

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

scientific article

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

scientific article

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).

scientific article published in October 2017

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

scientific article

SEOM clinical guideline for the management of malignant melanoma (2017).

scientific article published on 7 November 2017

SEOM guidelines for the management of Malignant Melanoma 2015

scientific article

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience

scientific article published on 17 March 2016

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

scientific article

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

scientific article

Vasculitic neuropathy induced by pembrolizumab

scientific article published on 17 November 2016

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

scientific article published on 19 December 2016

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

scientific article

[New treatments for germ cell tumors with poor prognosis]

scientific article published on 01 July 2000

Paulina is supported by:

About Paulina

Help